CCL2 and metabolic dysfunction-associated steatotic liver disease: Scoparone has been found to promisingly ameliorate the pathological alterations and prevent the development of HCC from nonalcoholic fatty liver disease (NAFLD) in a NAFLD-HCC mouse model by modulating p38 MAPK/Akt/NF-κB signaling cascade, with deactivation of MAPK/Akt pathway and downregulation of NF-κB, TNF-α, monocyte chemoattractant protein-1 (MCP-1), iNOS, COX-2, and MMP9 expressions [275].